Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Join Canadian Insider Club or Club Ultra to Keep Your Edge

Times are changing, ad revenues are plunging, and Canadian data costs have jumped.

Starting this summer, we will be limiting Canadian company page views to 10 per month for non-members.

Canadian Insider Club members will continue to get Google ad-free and unlimited access to canadianinsider.com.

Join the club to keep your edge! For a limited time, use coupon code SAVE99 to save $99* off a Canadian Insider Club Membership.

*Save $99 on the first year of a new Canadian Insider Club or Canadian Insider Club Ultra membership. Subsequent auto-renewals will be at the standard rate unless canceled. Limited time offer.

IMV Inc. (T:IMV)

Business Focus: Biotechnology & Medical Research

INK Edge Outlook

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for IMV within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Aug 12, 2020 07:05 ET
IMV Inc. Announces Second Quarter 2020 Financial Results
IMV Inc. (the “Company” or “IMV”) (TSX: IMV; NASDAQ: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announced financial results for the second quarter ended June 30, 2020 and provided an update on its clinical and operational progress.
Read full article
Aug 05, 2020 07:05 ET
IMV Receives Funding From Canadian Governmental Agencies for COVID-19 Vaccine Phase 1 Clinical Study
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announced that Canadian government agencies will contribute up to CA$4.75 million to advance Phase 1 clinical development of its vaccine candidate, DPX-COVID-19, for the prevention of COVID-19 infection caused by the novel coronavirus SARS-COV-2.
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
2.18
--
--
Price to Sales - TTM
754.90
13.63
10.04
Price to Book - most recent quarter
--
4.84
2.94
Price to Cash Flow per share - TTM
--
12.13
10.75
Price to Free Cash Flow per share - TTM
--
58.23
18.68
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Jul 31, 2020379,464-1,568,918
Jul 15, 20201,948,3821,589,554
Jun 30, 2020358,828-93,648
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

IMV Inc. is a clinical-stage biopharmaceutical company focused on immunotherapy in oncology. The Company's drug delivery platform (DPX) enables the programming of immune cells in vivo. The Company's lead candidate, DPX-Survivac, is a T cell-activating immunotherapy combining DPX with a specific tumor target: Survivin. DPX-Survivac is a monotherapy in ovarian cancer and in combination with Merck's Keytruda across multiple cancer indications.

See business summary

 

Twitter

Search (past week) for $IMV.CA